Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grafalon versus Thymoglobulin induction in high-risk kidney transplant recipients
2026-526938-23-00Phase 4Authorised
- Sponsor
- Foundation for the Incentive of Research
- Start
- Oct 2026
- Modality
- Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of antithymocyte globulin rabbit and antithymocyte globulin in chronic kidney disease (CKD) (2 arms), sponsored by Foundation for the Incentive of Research. Primary endpoint: Lymphocyte values throughout follow-up. Planned start Oct 2026; status: authorised.
02
Drugs
antithymocyte globulin rabbitantithymocyte globulin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2026-526938-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526938-23-00.